VANCE DOLLY 4
4 · RIGEL PHARMACEUTICALS INC · Filed Apr 2, 2021
Insider Transaction Report
Form 4
VANCE DOLLY
SVP, Gen. Counsel, Corp. Sec.
Transactions
- Award
Stock Option (Right to Buy)
2021-04-01+37,500→ 37,500 totalExercise: $2.42Exp: 2030-02-06→ Common Stock (37,500 underlying)
Footnotes (2)
- [F1]The reporting person was granted a performance-based option to purchase 37,500 shares of common stock on February 6, 2020. Thus, the exercise price of this option is $2.42 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On April 1, 2021, it was determined that the performance metric had been met.
- [F2]The option was fully vested on April 1, 2021, the date the performance metric had been met.